Yamo Pharmaceuticals Announces Autism Trial Registry Following Global Surge in Family Interest
More Than 6,000 Inquiries Since May; Yamo Opens a Registration Site to Help Speed Phase 3 Enrollment NEW YORK, Oct. 9, 2026 /PRNewswire/ -- Yamo Pharmaceuticals LLC ("Yamo"), the developer of L1-79, an investigational drug for the core symptoms of autism spectrum disorder ("ASD"), today...
Read original article on All News Releases →